Comparative Pharmacology
Head-to-head clinical analysis: LENALIDOMIDE versus POMALIDOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LENALIDOMIDE versus POMALIDOMIDE.
LENALIDOMIDE vs POMALIDOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
None Documented
None Documented
Clinical Note
moderatePomalidomide + Digoxin
"Pomalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePomalidomide + Digitoxin
"Pomalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLenalidomide + Digitoxin
"Lenalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePomalidomide + Deslanoside
"Pomalidomide may decrease the cardiotoxic activities of Deslanoside."
Terminal half-life ~3 hours (range 2-5 h) in multiple myeloma patients; prolongation in renal impairment requires dose adjustment.
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
Renal: ~82% unchanged; fecal <5%; biliary negligible.
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent